


XMT-1001, which is being evaluated in clinical trials, is a water-soluble polymeric prodrug derivative of CPT<sup>63</sup> with an improved therapeutic window compared with CPT and irinotecan in human tumor xenograft models.<sup>64</sup> When administered intravenously, XMT-1001 releases camptothecin-20-(*N*-succinimido-glycinate) (CPT-SI), CPT, and camptothecin-20-(*N*-succinamidoyl-glycinate) (CPT-SA) over an extended time period (Figure 13.33).

Analogs of fumagillin (see Chapter 11, Section 6.3) have also been studied as Fleximer<sup>®</sup> conjugates. XMT-1107 is a prodrug of XMT-1191, a first-in-class antiangiogenic compound with broad



**FIGURE 13.33**

XMT-1001, a Fleximer<sup>®</sup>-derived camptothecin prodrug.